Compare LPL & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LPL | APGE |
|---|---|---|
| Founded | 1985 | 2022 |
| Country | South Korea | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.7B |
| IPO Year | 2004 | 2023 |
| Metric | LPL | APGE |
|---|---|---|
| Price | $4.45 | $82.97 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $109.67 |
| AVG Volume (30 Days) | ★ 2.0M | 561.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.35 | N/A |
| Revenue Next Year | $2.94 | N/A |
| P/E Ratio | $25.64 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.97 | $34.34 |
| 52 Week High | $5.67 | $95.32 |
| Indicator | LPL | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 48.09 |
| Support Level | $4.16 | $73.06 |
| Resistance Level | $5.07 | $84.56 |
| Average True Range (ATR) | 0.16 | 3.57 |
| MACD | -0.04 | -1.27 |
| Stochastic Oscillator | 27.16 | 16.29 |
LG Display Co Ltd is a South Korea-based company that is principally engaged in developing, manufacturing, and selling TFT-LCD and OLED display panels. The company's products consist of panels for notebook computers, monitors, televisions, smartphones, tablets, and others. The company conducts direct sales through overseas subsidiaries in several countries, including the United States, Germany, Japan, Taiwan, China, and Singapore. These subsidiaries conduct sales activities and offer technical support to clients. The company generates the majority of its revenue from overseas markets, with the rest from South Korea.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.